Site Map   |  Contact Us  |  Search
TNKase TNKase
TNKase

TNKase Dosing and Administration
Investigate the Molecule
Clinical Data
Publications and Resources
Relevant Links
Product Return and Replacement
Prescribing Information

  

   Get A Free Dosing Card



   TNKase

   TNKase Dosing and Administration
      All-In-One Kit
      Simple Weight-Tiered Dosing

TNKase Reconstitution and Administration

   Investigate the Molecule

   Clinical Data
      ASSENT-2 Study Design and Methodology
          Primary Endpoint Results: 30-Day Mortality
          Intracranial Hemorrhage (ICH) and Stroke
          Major Noncerebral Bleeds
          Transfusions
          Survival Probability Curves
      TIMI 10B Results for Systemic Fibrinogen Levels

   Publications and Resources

   Utilities
      Full Package Insert
      Contact Us
      Relevant Links
      Product Return and Replacement
      Get a TNKase Dosing Card
      Opt Out


Indication
For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.

Important Safety Information
TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information].

The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately.

In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information].

Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown.

Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered.

Please see full Prescribing Information for additional important safety information.





TNKase Dosing and Administration Investigate the Molecule Clinical Data Publications and Resources
Relevant Links Product Return and Replacement Full Package Insert Opt Out Home Terms and Conditions Privacy Policy


Please see TNKase full Prescribing Information. TNKase® (Tenecteplase). Activase® (Alteplase, recombinant).

© 2014 Genentech, Inc. All rights reserved. TNK0000729208
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990